Such factors include, but are not limited to: the impact of the COVID-19 pandemic and related policies and actions by governments or third parties; the failure to satisfy any of the closing conditions to the acquisition of Wright, including the receipt of any required regulatory clearances (and the risk that such clearances may result in the imposition of conditions that could adversely affect the expected benefits of the transaction); delays in consummating the acquisition of Wright; unexpected liabilities, costs, charges or expenses in connection with the acquisition of Wright; the effects of the proposed Wright transaction (or the announcement thereof) on the parties relationships with employees, customers, other business partners or governmental entities; weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products, including Wright products; potential supply disruptions; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to recall-related matters; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system; costs to comply with medical device regulations; changes in financial markets; changes in the competitive environment; our ability to integrate and realize the anticipated benefits of acquisitions in full or at all or within the expected timeframes, including the acquisition of Wright; and our ability to realize anticipated cost savings. We use cookies to customize content for your viewing and for analytics. Kalamazoo, MI 49002 After submitting your request, you will receive an activation email to the requested email address. Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. For investor inquiries please contact: Preston Wells, Vice President, Investor Relations at 269-385-2600 or preston.wells@stryker.com, For media inquiries please contact:Yin Becker, Vice President, Communications, Public Affairs and Corporate Marketing at 269-385- 2600 or yin.becker@stryker.com. © 2020, Nasdaq, Inc. All Rights Reserved. This communication is not a recommendation, an offer to purchase or a solicitation of an offer to sell ordinary shares of Wright or any other securities. PRESS RELEASE GlobeNewswire . Featured awards. American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, has advised Stryker B.V. that as of 5:00 p.m., Eastern Time, on August 27, 2020, the last business day prior to the announcement of the extension of the offer, 13,610,322 Wright Medical ordinary shares (excluding Wright Medical ordinary shares tendered pursuant to guaranteed delivery procedures), representing approximately 10.5% of the outstanding Wright Medical ordinary shares, have been validly tendered pursuant to the tender offer and not properly withdrawn and an additional 729,308 Wright Medical ordinary shares, representing approximately 0.6% of the outstanding Wright Medical ordinary shares, had been tendered pursuant to guaranteed delivery procedures. Aug. 28, 2020, 01:30 PM. Innisfree M&A Incorporated is acting as information agent for the tender offer. nodes[i].dataset.subscription : nodes[i].getAttribute('data-subscription'); if(status ==='true') {nodes[i].checked = true;}}};var nodes = document.querySelectorAll('#form1783 select[data-value]'); if (nodes) { for (var i = 0; i < nodes.length; i++) { var node = nodes[i]; var selectedValue = node.dataset ? In addition, Wright shareholders may obtain free copies of the tender offer materials by contacting Innisfree M&A Incorporated, the information agent for the tender offer, toll free at (888) 750-5834. Flow diverters enable physicians to treat their patients suffering from brain aneurysms without ever entering the sac of the aneurysm itself. Additional Information and Where to Find It. Requests for documents and questions regarding the tender offer may be directed to Innisfree M&A Incorporated by telephone, toll-free at (888) 750-5834 for shareholders, or collect at (212) 750-5833 for banks and brokers. Find the latest press releases from Stryker Corporation Common Stock (SYK) at Nasdaq.com. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. The tender offer will continue to be extended until all conditions are satisfied or waived, or until the tender offer is terminated, in either case pursuant to the terms of the purchase agreement and as described in the Schedule TO.

Zizzy Fanart, Szabadság, Szerelem English Subtitle, Volume Of A Cube, Maria B Pret, Doc Shaw Shows, Guerrilla Games Website, Clear Cookies Chrome Extension, After We Collided Google Drive, Terraria Angel Treads Or Firestorm Boots, Transformers Revenge Of The Fallen Constructicon Devastator, Best Moth Stories, Lance Burton Wife, Thomas Pridgen The Big Drum Solo, Lego Batman 3: Beyond Gotham - Cheat Codes, What Time Is The AP World History Exam 2020, Dele Alli Best Friend, Real Vikings, Danny Tenaglia Live Stream, Mykenna Dorn Fashion, Lampard Net Worth, Thomas Lang Website, Sergey Konovaltsev, Everything Everything Re Animator Review, Banded Water Snake, Amazon Meaning,